Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

RACP > Monoclonal Ab's > Flashcards

Monoclonal Ab's Flashcards

1
Q

Abatacept

A

CTLA4 fusion protein –> blocks CD80/CD86 –> prevents binding of T cell CD28 to APC CD80/CD86 –> prevents T cell activation RA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Anakinra

A

Recombinant form of human IL-1 Autoinflamm diseases, refractory RA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Nivolimab

A

PD-1 antibody –> binds PD-1 on T cells to prevent binding with PD-L1 from tumour cells –> reactivation of tumour T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Co-stimulatory pathway modulators

A

Abatcept, Ipilimumab CTLA4 pathway Nivoliumab, Pembrolizumab PD-1 antibody Atezolizumab, Tixolinumab PD-L1 antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Mepolizumab

A

IL-5 antibody Severe refractory eosinophilic asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Atezolizumab

A

PD-L1 antibody –> binds PD-L1 on tumour cells to prevent binding with PD-1 from T cells –> reactivation of tumour T cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Rituximab

A

CD20 antibody Removes B cells from circulation for 6-9/12 Haematological malignancies, RA, SLE, immune thrombocytopaenia, autoimmune haemolysis, ANCA vasculitis, cryoglobulinaemia, MS, pemphigus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Ipilimumab

A

CTLA4 blcoker –> prevents binding of T cell CTLA4 to APC CD80/CD86, but maintains T cell stimulation Melanoma, prostate Ca, lung Ca

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Golimumab

A

TNF-alpha

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Tocilizumab

A

IL-6 antibody Refractory RA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Idarucizumab

A

Monoclonal antibody binds to Dabigatran & metabolites with very high affinity (300x affinity of dabigatran) Dabigatran reversal agent for life threatening bleeding or emergency surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Lorlatinib

A

EML4-ALK inhibitor (3rd generation) AML4/ALK = aberrant active fusion protein present in ~5% of lung adenoCa Non-curable EML4/ALK positive lung adenoCa This is now standard of care, superior to crizotinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Sorafenib

A

Multi-kinase inhibitor: Raf signalling, VEGF, PDGF, C-kit HCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Dasatanib

A

BCR-Abl inhibitor

BCR-Abl positive CML

GIST Disease progression on imatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Natalizumab

A

Alpha-4 integrin antibody –> blocks T cell entry into brain and gut (Brain homing T cells express alpha-4-beta-1 which binds VCAM-1 expressed on brain endothelium) Multiple sclerosis, Crohn’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

EML4-ALK inhibitors

A

Crizotinib (1st generation) Ceritinib (2nd generation) Alectinib (2nd generation) Lorlatinib (3rd generation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Traztuzumab

A

HER2 Inhibits ligand independent HER2 signalling by preventing dimerization of HER2 R –> cell mediated cytotoxicity HER2+ breast Ca (Herceptin)

18
Q

Benralizumab

A

IL-5 R antibody –> blocks Th2 pathway Asthma

19
Q

Pembrolizumab

A

PD-1 antibody –> binds PD-1 on T cells to prevent binding with PD-L1 from tumour cells –> reactivation of tumour T cells

20
Q

Crizotinib

A

EML4-ALK inhibitor (1st generation) AML4/ALK = aberrant active fusion protein present in ~5% of lung adenoCa Non-curable EML4/ALK positive lung adenoCa

21
Q

Infliximab

A

TNF-alpha

22
Q

Dabrafenib

A

BRAF V600E inhibitor Melanoma (BRAF V600E mutation seen in up to 80% of melanoma)

23
Q

Certolizumab

A

TNF-alpha

24
Q

Sunitinib

A

VEGF inhibitor

Metastatic renal cell Ca

25
Q

Bevacizumab

A

VEGF antibody Metastatic CRC in combination with chemo

26
Q

Basiliximab

A

IL-2 R antibody Renal transplant

27
Q

TNF-alpha immunotherapies

A

Infliximab, Adalimumab, Certolizumab, Golimumab

Monoclonal Ab’s against TNF-alpha Etanercept Soluble TNF-alpha receptor

28
Q

Nilotinib

A

BCR-Abl inhibitor BCR-Abl positive CML GIST Disease progression on imatinib

29
Q

Etanercept

A

Soluble TNF-alpha receptor

30
Q

Vemurafenib

A

BRAF V600E inhibitor Melanoma (BRAF V600E mutation seen in up to 80% of melanoma)

31
Q

Adalimumab

A

TNF-alpha

32
Q

Daclizumab

A

IL-2 R antibody Renal transplant

33
Q

EGFR therapies

A

Erlotinib (1st generation, reversible) Gefitinib (1st generation, reversible) Afatinib (2nd generation, irreversible) Osimertinib (3rd generation)

Incurable EGFR positive lung adenoCa Cetuximab (antibody against EGFR) Metastatic CRC, KRAS, BRAF wild type only Head and neck Ca NSCLC

34
Q

Eculizumab

A

Antibody to C5 of complement cascade Paroxysmal nocturnal haemoglobinuria

35
Q

Tixolinumab

A

PD-L1 antibody –> binds PD-L1 on tumour cells to prevent binding with PD-1 from T cells –> reactivation of tumour T cells

36
Q

Secukinumab

A

IL-17 antibody –> blocks Th17 activation Psoriasis, PA, AS Makes Crohn’s worse

37
Q

Vedolizumab

A

Alpha-4-beta-7 ntegrin antibody –> blocks T cell entry into gut (Gut homing T cells express alpha-4-beta-7 which binds MadCAM expressed on gut endothelium) IBD - Crohn’s, UC

38
Q

Omalizumab

A

IgE antibody –> blocks Th2 pathway Severe allergic asthma Chronic spontaneous urticaria

39
Q

Ustekinumab

A

Binds p40 subunit of IL-12 & IL-23 –> blocks Th1 and Th17 activation Psoriasis, PA, AS, ?Crohn’s

40
Q

Ceritinib

A

EML4-ALK inhibitor (2nd generation) AML4/ALK = aberrant active fusion protein present in ~5% of lung adenoCa Non-curable EML4/ALK positive lung adenoCa Brain mets on crizotinib (higher brain penetration)

41
Q

Imatinib

A

BCR-Abl inhibitor BCR-Abl positive CML GIST

RACP (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions